miR Scientific Appoints Laurence Klotz, M.D., FRCSC, as Chief Medical Officer

NEW YORK, July 9, 2018 /PRNewswire/ -- miR Scientific, LLC formerly known as miR Diagnostics (miR or the Company), a precision molecular bioscience company, today announces the appointment of Laurence Klotz, M.D., FRCSC, CM, to the role of Chief Medical Officer, effective immediately and sponsorship of the Fourth Friends of Israel Urological Symposium also co-chaired by Dr. Klotz that was held from July 3-5 in Israel.

"Laurence brings a wealth of urological expertise to miR as a clinical trialist, urologic oncologist and collaborative research partner during an exciting time in our company's growth," said Sam Salman, Chief Executive Officer of miR Scientific.  "His ability to synthesize his decades of experience as an industry leader will help guide miR Scientific's clinical development efforts and regulatory strategies.  With the addition of Laurence to our team, we are well positioned to maximize the high priority opportunities available to us through our urogenital cancer platform, which includes advanced, non-invasive liquid biopsy screening tests to diagnose bladder and prostate cancers. His active participation in this year's Friends of Israel Urological Symposium highlights the esteemed position he holds amongst world renowned colleagues."

Dr. Klotz currently serves as the Chairman of the World Urologic Oncology Federation and Member of the Institute of Medical Science and Graduate Faculty at the University of Toronto since July 2005.  He also serves as the Chairman of the Canadian Urology Research Consortium of Toronto since July 2004.  Since May 2000, he serves as Professor of Surgery at the University of Toronto and has been an active staff and is the past chief at the Division of Urology at Sunnybrook Health Sciences Centre in Toronto since 1985.  He holds numerous distinctions and research awards including the Richard Williams Award from the American Urological Association, which is presented to individuals for their outstanding and impactful research in the field of prostate cancer, the Dean's lifetime achievement award from the University of Toronto, and the Order of Canada, Canada's highest civilian honor.  Dr. Klotz received a BSc and MD from the University of Toronto. 

"miR Scientific's platform has the prospect to be truly transformative," said Dr. Klotz.  "It is rare to be presented with an opportunity to develop breakthrough technologies with such significant potential that have promising data in two urologic cancers.  The prospect that miR Scientific can disrupt legacy diagnostic methodologies such as prostate-specific antigen (PSA) screening through the Company's Sentinel™ Prostate Diagnostic Test (miR-PDx) for prostate cancer is notable.  I look forward to this exciting challenge and the potential to have a meaningful impact on patients and their families."

"We look forward to working with Dr. Klotz, who is based in Toronto, to expand our clinical development in strategic hubs within North America," commented Robert Tenniswood, President of miR Scientific Canada, Inc.  "His contributions can more rapidly expand our pipeline dedicated to advancing miR's urogenital cancer platform."   

About miR Scientific, LLC

A subsidiary of NRS Health and Wellness, LLC, miR Scientific is a precision molecular bioscience company that creates and delivers scalable breakthrough technologies for the provision of accessible diagnostic, prognostic, monitoring and companion products and services for large at-risk cancer populations.  miR's pipeline of products under the miR Sentinel^TM platform includes the Prostate Cancer Assay Test, a urine-based liquid biopsy test with unprecedented accuracy that has the potential to save thousands of men from suffering possible severe side effects of unnecessary prostate cancer treatments. The Company was founded in 2014 as a commercial spin-out from the State of New York University at Albany's Cancer Research Center and currently has operations in Rensselaer, New York City, Israel and Canada.  For more information, visit www.mirscientific.com.

Forward-Looking Statements

This press release contains forward-looking statements, including with respect to the clinical development and prospects for commercialization of the Company's product candidates, the impact and potential of the Company's technology, and the expansion of the Company's platform.  These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including delays or complications in clinical trials and attainment of regulatory approvals.  The events and circumstances discussed in such forward-looking statements may not occur, and the Company's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to the Company as of the date of this release.

SOURCE miR Scientific, LLC